Aptevo Therapeutics Inc. (APVO)
APVO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1671584/000095017024025428/0000950170-24-025428-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | APVO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001671584 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2022
| Line | Value |
|---|---|
| Revenue | $3.1M |
| Net income | $8.0M |
| Operating income | -$28.6M |
| Net margin | 257.8% |
| Operating margin | -919.7% |
| Revenue growth | -74.7% |
| Cash | $22.6M |
| Total assets | $34.2M |
| P/E (computed) | 0.2× |
| P/S (computed) | 0.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "When considered in aggregate, these factors raise substantial doubt about our ability to continue as a going concern for the one-year period from the date of issuance of these financial statements." | 10-Q 2026-08-14 |
| Cash and burn | $9.8M cash; operating cash flow -$6.3M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,801,970 (2026-08-14); 3,287,918 a year earlier; 11,523,716 three years earlier. 1y figure adjusted for splits (1-for-18 overall); 3y figure adjusted for splits (1-for-586080 overall). | Cover page 2026-08-14 |
| Reverse splits, 3 years | 4; latest 1-for-18 on 2025-12-30 | Source 2025-12-30 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-10-30 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Baker Tilly US, LLP, Seattle, Washington, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-06-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $20K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$6.4M | -$5.5M | $9.8M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$6.7M | -$8.0M | $14.5M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$5.8M | -$5.2M | $21.6M | No debt tags | Needs four quarters | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | Not filed | -$7.5M | -$6.7M | $21.1M | No debt tags | Needs four quarters | 10-Q 2025-11-06 |
| Q2 2025 2025-06-30 | Not filed | -$6.2M | -$7.1M | $9.4M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$6.4M | -$6.6M | $2.1M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$6.3M | -$5.8M | $8.7M | No debt tags | Needs four quarters | 10-K 2026-03-26 |
| Q3 2024 2024-09-30 | Not filed | -$5.1M | -$5.2M | $7.8M | No debt tags | Needs four quarters | 10-Q 2025-11-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-10-30 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | PRE 14A | 2026-11-12 |
Source: SEC EDGAR submissions feed, 747 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -52.1% |
| 1 month | -65.7% |
| 3 months | -82.5% |
| Year to date | -93.7% |
| 1 year | -97.7% |
| From 52-week high | -97.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KAPA | Kairos Pharma Ltd. | $0.4069 | -10.30% | $1.4M |
| ARTL | Artelo Biosciences Inc. | $1.70 | -17.87% | $1.6M |
| ELAB | PMGC Holdings Inc. | $1.66 | +5.06% | $1.3M |
| ENLV | Enlivex Ltd. | $1.12 | -5.88% | $1.7M |
| SXTP | 60 Degrees Pharmaceuticals Inc. | $0.4938 | -4.65% | $1.7M |
| HCWB | HCW Biologics Inc. | $0.8000 | +3.48% | $1.8M |
| BDRX | Biodexa Pharmaceuticals plc American Depositary Shs | $2.24 | -6.28% | $1.2M |
| XRTX | XORTX Therapeutics Inc. Common Shares | $1.04 | -5.45% | $1.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier